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license (http://creativeamyloid-beta 1–42 (Ab [1–42]) in cerebrospinal fluid demonstrate significant variability and lack
of standardization to reference measurement procedures (RMPs). We report analytical performance
data for the novel Elecsys b-amyloid (1–42) assay (Roche Diagnostics).
Methods: Lot-to-lot comparabilitywas testedusingmethod comparison. Performanceparameterswere
measured according to Clinical & Laboratory Standards Institute (CLSI) guidelines. The assay was
standardized to a Joint Committee for Traceability in Laboratory Medicine (JCTLM) approved RMP.
Results: Limit of quantitation was,11.28 pg/mL, and the assay was linear throughout the measuring
range (200–1700 pg/mL). Excellent lot-to-lot comparability was observed (correlation coefficients
[Pearson’s r] .0.995; bias in medical decision area ,2%). Repeatability coefficients of variation
(CVs) were 1.0%–1.6%, intermediate CVs were 1.9%–4.0%, and intermodule CVs were 1.1%–3.9%.
Estimated total reproducibilitywas 2.0%–5.1%.Correlationwith the RMPwas good (Pearson’s r, 0.93).
Discussion: The Elecsys b-amyloid (1–42) assay has high analytical performance that may improve
biomarker-based AD diagnosis.
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Variability1. Introduction
The incidence of Alzheimer’s disease (AD) is expected to
triple in both the United States and Europe in the next
decades, resulting in a substantially increased health careuthor. Tel.: 146-31-343-1791; Fax: 146-31-343-
aj.Blennow@neuro.gu.se
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e Authors. Published by Elsevier Inc. on behalf of Alzheim
commons.org/licenses/by-nc-nd/4.0/).burden [1,2]. Disease-modifying treatments (DMTs) for
AD are in development but none are yet available [1]
because of the high attrition rate observed in clinical trials
[3]. Importantly, most of the agents in development for
AD directly target the amyloid pathology of AD. The devel-
opment and potential availability of these treatments create
the need for reliable diagnostic tests that can accurately iden-
tify patients with amyloid pathology, who will likely benefit
most from these agents. Availability of a DMT would alsoer’s Association. This is an open access article under the CC BY-NC-ND
T. Bittner et al. / Alzheimer’s & Dementia 12 (2016) 517-526518increase the demand for techniques to improve recognition
of AD in clinical practice, particularly in the early stages
of the disease (mild cognitive impairment [MCI] due to
AD, or prodromal AD). Cognitive symptoms are mild and
diffuse, which preclude the possibility of differentiating
early, prodromal AD from other causes of MCI.
The most recent diagnostic criteria for AD recommend
use of in vivo biomarkers of AD pathology to enhance diag-
nostic accuracy [4]. Candidate biomarkers include decreased
amyloid-beta 1–42 (Ab [1–42]) in the cerebrospinal fluid
(CSF), alone or in conjunction with increased total tau or
phosphorylated tau, and increased retention of amyloid-
targeting radiotracers detected by positron emission tomog-
raphy (PET). CSFAb (1–42) is altered early in the course of
the illness [5,6], and CSF Ab (1–42) levels correlate well
with neuropathologic findings (neuritic plaques) consistent
with AD [7,8], as well as with PET-based measurements
of amyloid pathology [9–11].
These findings support the use of CSF Ab (1–42) in
research diagnostic criteria. However, issues with currently
available CSF Ab (1–42) assays limit their applicability as
diagnostic devices worldwide. These issues include high
lot-to-lot variability for enzyme-linked immunosorbent as-
says (ELISAs) [12], as well as between-laboratory vari-
ability associated with differences in laboratory procedures
and analytical techniques, as assays are most often run
manually [13]. In addition, the historical lack of availability
of a reference measurement procedure (RMP) for quantita-
tion of CSF Ab (1–42) has resulted in difficulties in
comparing results across assays [14]. Taken together, these
shortcomings prevent the establishment of universal diag-
nostic cutoffs for CSF biomarkers. Finally, available assays
have long incubation times, and as most assays are based on
the 96-well plate immunoassay format, for financial reasons,
laboratories must await a high enough number of samples to
justify analysis. Therefore, turnaround times for test results
may be as long as several weeks.
The Elecsys b-amyloid (1–42) assay (Roche Diagnostics)
is a novel, fully automated, electrochemiluminescence
immunoassay, using the sandwich test principle, for quanti-
tation of Ab (1–42) in human CSF. In this study, we describe
the technical performance of this assay, including its stan-
dardization Joint Committee for Traceability in Laboratory
Medicine (JCTLM) approved RMP.2. Materials and methods
2.1. Materials
The assay process involves twodiscrete incubation steps of
9-minute duration. During the first incubation, 40 mL of sam-
ple is incubated with two monoclonal antibodies specific to
Ab (X–42) (biotinylated 21F12) and Ab (1–X) (ruthenium-
labeled 3D6), respectively [15], resulting in formation of a
sandwich complex that is specific for the detection of Ab
(1–42). In the second incubation, after addition ofstreptavidin-coated magnetic microparticles, the sandwich
complex becomes bound to the solid phase. Formeasurement,
the reaction mixture is aspirated into a measuring cell where
the microparticles are magnetically captured onto the surface
of an electrode. Unbound substances are then removed by
washing. Application of a voltage to the electrode induces
chemiluminescent emission of photons from the ruthenium
complex, which are quantified by a photomultiplier.
The assay uses two-point recalibration of a master cali-
bration curve with two supplied lyophilized calibrators in a
buffer matrix. The master curve is generated at each lot stan-
dardization by Roche Diagnostics and is included in the bar-
code of the kit. After reconstitution of the lyophilisate, the
calibrators are ready to use. Recalibration of an existing re-
agent pack must be performed if left on board the instrument
for .7 days, and recalibration of an existing lot with a new
reagent pack must be performed if the last calibration was
.4 weeks ago. The assay is run on the cobas e 601 analyzer
platform, with a throughput of 170 samples per hour, which
was used for all experiments reported here.
Five separate production lots of the final assay composi-
tion have been produced and evaluated for the Elecsys b-am-
yloid (1–42) assay: lots MP01, MP03, P02, P03, and P04.
The first lot, MP01, was unavailable for some of the exper-
iments discussed as supplies had been exhausted, whereas
the most recent lot, P04, was not included in some experi-
ments as they were completed before availability of this lot.
2.1.1. Substances
The peptides used were as follows. Ab (1–42) was ob-
tained from R-Peptide (#A-1163-1), Bogart, GA, USA. Ab
(1–38) was obtained from Bachem (H-1194), Bubendorf,
Switzerland. Ab (1–40) was obtained from Sigma-Aldrich
(A0189), St. Louis, MO, USA. Drugs used in interference
experiments are shown in Supplementary Table 1 and were
all obtained from Sigma-Aldrich (with the exception of riva-
stigmine). Other endogenous substances were obtained from
Roche Diagnostics GmbH, Penzberg, Germany. Artificial
CSF (aCSF) was prepared according to the method of Jensen
et al. [16].2.2. Methods2.2.1. Analytical sensitivity
Limit of quantitation (LoQ) was derived according to the
method described in Clinical & Laboratory Standards Insti-
tute (CSLI) document EP17-A2 [17] for lots MP03, P02, and
P03. Four human CSF pools were measured both undiluted
and after dilution to concentrations between 2.5 and 20 pg/
mL using aCSF as diluent. LoQ was specified as the lowest
observed averaged Ab (1–42) concentration that fulfilled the
specification for relative total error of 30%. For both undi-
luted and diluted samples, measurements were performed on
two different cobas e 601 analyzers with two runs per day on
each analyzer over three consecutive days, for a total of 12 runs.
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Linearity was assessed using four separate dilution series,
according to the method described in CLSI EP6-A [18]. Two
dilution series were prepared using a human CSF pool, and
two dilution series were prepared with aCSF. Further details
are provided in Supplementary Methods.
2.2.3. Standardization of the Elecsys b-amyloid (1–42)
assay to liquid chromatography–tandem mass spectrometry
RMP
The Elecsys b-amyloid (1–42) assay was standardized to
the JCTLM approved RMP for quantitation of Ab (1–42) in
human CSF, based on liquid chromatography–tandem mass
spectrometry (LC-MS/MS) [19]. Reference standardization
was performed with 372 individual human CSF samples
measured with both the RMP [19] and the Elecsys b-amyloid
(1–42) assay. From these 372 samples, 362 were within the
measuring range of the Elecsys b-amyloid (1–42) assay and
were, therefore, used in a method comparison. All subse-
quent assay lots were standardized to a panel of 21 human
CSF pools with Ab (1–42) concentrations ranging from
150 to 2300 pg/mL, with target values that can be traced
back to the RMP. This process ensures traceability of each
new assay lot back to the RMP.2.2.4. Lot-to-lot comparison
The comparability of assay lots MP03, P02, and P03 to
each other (i.e., MP03 vs. P02, MP03 vs. P03, and P02 vs.
P03) was tested using method comparison according tomeasured concentration of the spiked sample2known concentration of the nonspiked sample
crossreactant concentration
!100CLSI EP09-A3 [20]. A series of individual human CSF sam-
ples (n 5 100) with Ab (1–42) concentrations covering the
measuring range of the assay (200–1700 pg/mL) was
measured with each assay lot. Comparability of the lots
was assessed by correlation and regression analysis [21].
2.2.5. Interference
2.2.5.1. Endogenous substances
The potential for interference of endogenous substances
with the Elecsys b-amyloid (1–42) assay was tested accord-
ing to CLSI EP7-A2 [22] and CLSI I/LA30-A [23] with hu-
man CSF pools and aCSF pools spiked with calibrator
peptide to reach Ab (1–42) concentrations in the upper re-
gion of the measuring range. The endogenous substances
tested were Intralipid (to test for the effect of lipemia),
biotin, bilirubin, hemoglobin, rheumatoid factor, human
serum albumin, human immunoglobulin (Ig) G, humanIgM, human IgA, and human anti-mouse antibodies. Further
details are provided in Supplementary Methods.
2.2.5.2. Drugs
The potential for interference of co-administered drugs
with the Elecsys b-amyloid (1–42) assay was assessed by
measuring Ab (1–42) concentrations in CSF samples with
and without the presence of the potentially interfering
drug. Human CSF pools were used in this experiment. A to-
tal of 31 drugs tested, listed in Supplementary Table 1,
included some frequently administered in the general popu-
lation, as well as a wider selection of drugs frequently
administered in elderly patients at risk for, or experiencing
symptoms of, AD. Further details are provided in
Supplementary Methods.
2.2.6. Cross-reactivity
The potential for cross-reactivity of the Elecsys b-amy-
loid (1–42) assay with other amyloid peptides was tested
for Ab (1–38) and Ab (1–40) according to CLSI EP7-A2
[17]. These two peptides were specifically chosen because
they partially share the amino acid sequence of the epitopes
of the assay antibody and because they occur more abun-
dantly in CSF than Ab (1–42) [24]. Three human CSF sam-
ples with nominal Ab (1–42) concentrations of
approximately 500, 800, and 1100 pg/mL were spiked
with varying concentrations of the two potential cross-
reactants (0, 2.5, 5, 10, and 20 ng/mL) before measurement
with the Elecsys b-amyloid (1–42) assay. The cross-
reactivity percentage was calculated as:Absence of cross-reactivity was established if the cross-
reactivity was 10%.2.2.7. Hook effect
To test for the presence of a high-dose hook effect with Ab
(1–42), two dilution series were established with two sepa-
rate CSF pools (aCSF for lot MP01 and human CSF for
lots P02, P03, and P04). The two pools were spiked with cali-
brator peptide up to a concentration .11,000 pg/mL. For
each CSF pool, a dilution series in aCSF was prepared to
achieve Ab (1–42) concentrations of 0–.11,000 pg/mL.2.2.8. Reagent and calibration stability
Reagent and calibration stability were assessed in a series
of experiments that tested the impact of various storage con-
ditions on the reagents. Further details are provided in
Supplementary Methods.
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(1–42) recovery for nine separate samples (human CSF
pools and aCSF pools spiked with calibrator peptide) with
varying Ab (1–42) concentrations covering the measuring
range of the assay (200–1700 pg/mL) and two controls
before and after exposure to the conditions and time intervals
specified in the Supplementary Methods. Samples and con-
trols were tested in duplicate.
2.2.9. Precision
Repeatability (within-run precision) and intermediate
(within-laboratory) precision were assessed according to
CLSI EP05 [25] over 21 days with two runs per day and
two determinations per run using nine CSF samples (hu-
man CSF pools, aCSF pools spiked with calibrator pep-
tide). Intermodule (between-instrument) precision was
assessed across four cobas e 601 modules using five CSF
samples (human CSF pools, aCSF pools spiked with cali-
brator peptide).
2.2.10. Multicenter performance evaluation
The multicenter performance evaluation study aimed to
assess reproducibility of the Elecsys b-amyloid (1–42) assay
under varying conditions (i.e., different sites, different lots,
and multiple runs on different days with repetitions). Five
different human CSF sample pools covering the measuring
range of the assay and two artificial samples (controls) were
analyzed to evaluate the external reproducibility. Four
different sites (University of Gothenburg, Sweden; VU Uni-
versity Medical Center, Amsterdam, the Netherlands; Wash-
ington University at St. Louis, MO, USA; and Covance
Indianapolis, IN, USA) and three different assay lots
(MP03, P02, and P03) were included in the study, with two
sites using all three lots and two sites using two lots. The study
design was adapted from CLSI-EP15-A2 [26], with two runs
per day for each lot and each sample over 5 days. The total
reproducibility and variance components were calculated
for each of the samples in terms of coefficient of variationTable 1
Target and measured concentrations, and total error, for CSF samples in limit of q
Sample
number
Dilution level
(relation to
original sample %)
Target
concentration
(pg/mL)
Mean measured
concentration
(pg/mL) SD (pg
CSF1 100 171 175.4 7.53
2.92 5 1.22 1.20
8.77 15 9.84 1.15
CSF2 100 175 175.5 4.40
2.86 5 1.72 1.51
8.57 15 11.67 1.33
CSF3 100 198 196.75 5.46
2.53 5 1.30 1.19
7.58 15 11.28 1.18
CSF4 100 152 163.0 4.16
3.29 5 1.87 1.17
9.87 15 11.32 0.89
Abbreviations: CSF, cerebrospinal fluid; SD, standard deviation.(CV) % by variance components analysis using the analysis
of variance type 1 approach for unbalanced data, including
the components site, lot, day, run, and within-run precision.
Confidence intervals (CIs; 95%) for the total reproducibility
were calculated based on the chi-square distribution and Sat-
terthwaite approximation for degrees of freedom.
Each site used one cobas e 601 analyzer and was first
familiarized with the instrument and the assay by running
the low and high assay controls in 21 repetitions on a sin-
gle day. In addition, a human CSF pool was run over
several days to allow the site to become familiarized
with CSF as sample material. Familiarization was fol-
lowed by a 10-day precision experiment, where each of
the two assay controls was measured in two runs per
day in duplicate. This experiment was used to set up
site-specific quality control rules for the controls, based
on site-specific target values and precision values derived
from this experiment.
3. Results
3.1. Analytical sensitivity
Target Ab (1–42) concentrations, measured Ab (1–42)
concentrations, total error, and relative total error for undi-
luted and diluted samples were determined for the four sepa-
rate CSF samples tested with MP03, P02, and P03 lots.
Based on these results, the LoQ for Ab (1–42) was calcu-
lated as 5.10 pg/mL for P03, 10.64 pg/mL for MP03, and
11.28 pg/mL for P02. Data from P02, the lot with the highest
LoQ, are listed in Table 1. The overall LoQ value across the
three lots was 11.28 pg/mL.3.2. Linearity
Linearity was demonstrated throughout the measuring
range (200–1700 pg/mL) for all four dilution series. These
results were consistent across the three separate assay lots
MP01, P02, and P03.uantitation experiment for lot P02
/mL) Bias (pg/mL) Total error (pg/mL) Relative total error (%)
4.42 8.73 5.10
3.78 3.97 79.38
5.16 5.29 35.25
0.50 4.43 2.53
3.29 3.61 72.27
3.33 3.59 23.92
1.25 5.60 2.83
3.70 3.89 77.72
3.73 3.91 26.05
11.0 11.76 7.74
3.13 3.34 66.84
3.68 3.79 25.27
T. Bittner et al. / Alzheimer’s & Dementia 12 (2016) 517-526 5213.3. Standardization of the Elecsys b-amyloid (1–42)
assay to LC-MS/MS reference method
Fig. 1 shows the method comparison between the Elecsys
b-amyloid (1–42) method and the LC-MS/MS reference
method within the measuring range (n 5 362 samples).
The correlation between the two methods (Pearson’s r)
was 0.93.3.4. Lot-to-lot comparison
The method comparison for the lot-to-lot comparability
experiments is shown in Fig. 2A–C. Excellent comparability
in terms of correlation and absolute values was observed be-
tween all lots. For lot MP03 versus lot P02, the intercept and
slope (Passing-Bablok linear regression analysis) were 9.76
(95% CI, 4.94–15.7) and 0.996 (95% CI, 0.985–1.00). For
lot MP03 versus lot P03, the intercept and slope were 18.3
(95% CI, 11.7–24.6) and 0.984 (95% CI, 0.972–0.994).
For lot P02 versus lot P03, the intercept and slope were
6.81 (95% CI, 0.993–15.9) and 0.987 (95% CI, 0.973–
1.00). The correlation coefficients (Pearson’s r) were 0.998
(lot MP03 vs. lot P02), 0.996 (lot MP03 vs. lot P03), and
0.997 (lot P02 vs. lot P03). The proportional bias between
all lots was ,2% in the medical decision area.3.5. Interference
3.5.1. Endogenous substances
No interference was observed with any of the three CSF
pools tested up to the highest concentrations of the endoge-
nous substances (data not shown).Fig. 1. Method comparison after standardization of the Elecsys Ab (1–42)
assay to the liquid chromatography–tandem mass spectrometry reference
method (Leinenbach et al.) [18].3.5.2. Drugs
Interference of drugs was within specifications for all
drugs with the lower drug concentration tested (C1) for
any of the three samples. Interference of drugs was also
within specifications for the higher drug concentration
tested (C2) for any of the three samples except for cefox-
itin (87.7% recovery at a drug concentration of 2500 mg/
L) and metformin (88.2% recovery at a drug concentration
of 12 g/L).3.6. Cross-reactivity
No significant cross-reactivity was observed with either
Ab (1–38) (cross-reactivity was 20.17% to 21.92% with
the 500-pg/mL sample, 20.24% to 21.88% with the 800-
pg/mL sample, and 20.42% to 21.72% with the 1100-pg/
mL sample) or Ab (1–40) (cross-reactivity was 20.40% to
21.12% with the 500-pg/mL sample, 20.57% to 21.36%
with the 800-pg/mL sample, and 20.76% to 22.76% with
the 1100-pg/mL sample).3.7. Hook effect
Across two separate dilution series for lot MP01, no hook
effect was observed up to 9000 pg/mL and beyond, which ex-
ceeds the upper end of the measuring range (1700 pg/mL) by
more than fivefold (Supplementary Fig. 1). This result was re-
produced in analysis of three further lots (P02, P03, and P04).3.8. Reagent and calibrator stability
The stability of reagents and calibrations exceeded specifi-
cations for all stability experiments. On-board calibration fre-
quency exceeded 7 days and lot calibration frequency
exceeded 4 weeks. On-board reagent stability was found to
be .4 weeks, whereas reagent stability at 2C–8C after first
opening was .8 weeks. Transport stability exceeded 1 week
at 25C.3.9. Precision
Repeatability CVs for human CSF pools were 1.0%–
1.6% and intermediate CVs were 1.9%–4.0% (Table 2). In-
termodule CVs were 1.1%–3.9% (Table 3).3.10. Multicenter performance evaluation
The five samples and two controls analyzed showed an
estimated total reproducibility (including all sources of vari-
ability—site, lot, day, run, and within-run; %CV) ranging
between 2.0% and 5.1% (Table 4). The estimated intersite
precision was 3.5% for all samples and the intermediate
(within-laboratory) precision ranged between 1.7% and
3.6% for all samples. The estimated repeatability (within-
run precision) was 2.7% for all samples. The estimated
lot-to-lot variability was 2.3% for all samples.
A B
C
Fig. 2. Comparison between assay lots for Elecsys Ab (1–42). (A) Lot P02 versus lot MP03. (B) Lot P03 versus lot MP03. (C) Lot P02 versus lot P03.
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Here, we describe the results of technical performance ex-
periments for a novel electrochemiluminescence assay for the
quantitation of Ab (1–42) in human CSF. The Elecsys b-am-
yloid (1–42) assay demonstrates low between-laboratory and
lot-to-lot variability and is standardized to an JCTLM
approved reference method [19], implying that use of this
assay might allow for establishment of cutoff concentrations
with global applicability and consistency over time.
The total reproducibility with the Elecsys b-amyloid
(1–42) assay over four different sites ranged between 2.0%and 5.1%. By comparison, available assays for CSF Ab
(1–42) demonstrate considerable variability between labora-
tories and between different lots. Results from the Alz-
heimer’s Association Quality Control (AAQC) program
(rounds 1–9, 2010–2012) showed that overall variability
for Ab (1–42) analysis was 17%–29% for INNOTEST
ELISA, 17%–38% for INNO-BIA AlzBio3, and 13%–36%
for Meso Scale Diagnostic (MSD) [13]. The improved vari-
ability of the Elecsys b-amyloid (1–42) assay in comparison
with commercially available assays has been confirmed in
the latest rounds of the AAQC program, which include the
Table 2
Repeatability and intermediate precision
Sample ID
Mean measured
concentration (pg/mL)
Repeatability (within-run precision) Intermediate precision (within-laboratory)
SD (pg/mL) %CV (upper limit of 95% CI) SD (pg/mL) %CV (upper limit of 95% CI)
Low control 470 3.66 0.8 (1.0) 7.614 1.6 (2.1)
High control 978 8.45 0.9 (1.1) 15.93 1.6 (2.1)
CSF1 249 2.91 1.2 (1.5) 5.14 2.1 (2.6)
CSF2 433 6.08 1.4 (1.8) 11.47 2.6 (3.3)
CSF3 619 6.79 1.1 (1.4) 15.56 2.5 (3.1)
CSF4 767 9.50 1.2 (1.6) 22.08 2.9 (3.6)
CSF5 816 8.01 1.0 (1.2) 15.30 1.9 (2.3)
CSF6 873 10.90 1.2 (1.6) 18.37 2.1 (2.6)
CSF7 931 11.64 1.3 (1.6) 36.87 4.0 (5.0)
CSF8 1069 12.26 1.1 (1.5) 21.03 2.0 (2.4)
CSF9 1456 23.01 1.6 (2.0) 37.60 2.6 (3.2)
Abbreviations: SD, standard deviation; CV, coefficient of variation; CI, confidence interval; CSF, cerebrospinal fluid.
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16 was 17%–27% for INNOTEST ELISA, 30%–40% for
INNO-BIA AlzBio3, 11%–13% for MSD, and 19%–57%
with EuroImmune/ADx, compared with 2.5%–3.0% for
the Elecsys b-amyloid (1–42) assay [27]. In round 17,
overall variability was 14%–19% for INNOTEST ELISA,
15%–17% for INNO-BIA AlzBio3, 20%–21% for MSD,
and 6.5%–8.2% with EuroImmune/ADx, compared with
1.9%–3.2% for the Elecsys b-amyloid (1–42) assay [28].
Notably, the Elecsys b-amyloid (1–42) assay has high
lot consistency—variability due to lot effect in the multi-
center performance evaluation study [CV] was 2.3%,
and the lot-to-lot method comparison experiments showed
a bias of ,2% in the medical decision area and correlation
coefficients (Pearson’s r) of .0.99 for all three assay lots.
The reduced lot-to-lot variability with the Elecsys b-amy-
loid (1–42) assay arises from the rigid lot standardization
process, which involves comparison with a panel of native
samples with target values traceable to an JCTLM
approved RMP [19]. Lack of standardization of current as-
says to a certified reference material or RMP is one of the
principal unmet needs in the quantification of Ab (1–42) in
CSF [14,29]. Without standardization, the apparent
concentration of the biomarkers measured is likely to
vary between assays, leading to difficulties withTable 3
Intermodule precision
Sample ID
Mean measured
concentration (pg/mL) SD (pg/mL) %CV
Low control 466 2.20 0.5
High control 977 7.60 0.8
CSF1 120 3.42 2.9
CSF2 247 3.60 1.5
CSF3 455 17.82 3.9
CSF4 670 7.65 1.1
CSF5 913 27.13 3.0
Abbreviations: SD, standard deviation; CV, coefficient of variation; CSF,
cerebrospinal fluid.interpretation and comparison of results between
laboratories using different assays, and thereby
preventing introduction of universal cutoff concentrations
to aid in the diagnosis of AD [14]. Universal cutoff concen-
trations are already applied for several biomarkers in clin-
ical routine, including HbA1c in diabetes mellitus [30].
The next step would be to apply the same concept also
to Ab (1–42) in CSF in patients with AD.
Our results demonstrate that the Elecsys b-amyloid (1–42)
assay is robust, with good analytical sensitivity and linearity
over the desired measuring range with no high-dose hook ef-
fect. Furthermore, the assay demonstrated good specificity,
with no cross-reactivity for Ab (1–38) or Ab (1–40). No inter-
ference of endogenous substances with the assay was noted,
and of the large number of drugs tested in interference exper-
iments, only cefoxitin and metformin exhibited any interfer-
ence with the assay. Furthermore, the drug interferences were
noted at concentrations much higher than expected therapeu-
tic levels (cefoxitin 2500 mg/L, expected therapeutic level in
CSF: 2.8 mg/L [31]; metformin 12 g/L, expected therapeutic
level in plasma: 1–2 mg/L [32]).
A potential limitation of this study, which remains appli-
cable to all studies using currently available immunoassays,
is the absence of a robust preanalytical sample handling pro-
cedure. The principal variables that have been demonstrated
to have significant effects on measured concentrations of Ab
(1–42) in CSF samples are tube material (polypropylene and
polystyrene) and CSF storage conditions (ambient tempera-
ture, number of freeze/thaw cycles before analysis) [33,34].
Although guidelines have been proposed to standardize
preanalytical procedures for AD biomarkers [34], these are
not yet universally adopted but are vital for introduction of
universal cutoffs.
As discussed, diagnosis based on CSF Ab (1–42) mea-
surements is not yet widely performed in routine clinical
practice, partly because of issues with available assays.
An alternative is PET imaging with amyloid-specific
radiotracer ligands, which is now an established diagnostic
tool, as three PET tracers are currently approved by the US
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nostic use. However, PET imaging has potential limitations,
including high cost, requirement for a PET scanning instru-
ment at the clinical center, and short half-lives of the (18F)
radiotracers used (requiring either a cyclotron at or near the
PET scanning center or rapid transport of the radiotracers to
the center from elsewhere [35]). Nevertheless, the FDA
approval of amyloid PET tracers [36–38] shows the
medical need for robust, reliable, and widely available
biomarkers to determine the presence of amyloid
pathology in clinical routine.
A frequently cited obstacle to the use of CSF as a source
for AD biomarkers is that obtaining samples from individ-
uals requires a lumbar puncture (LP) procedure, around
which there are a number of negative perceptions of poten-
tial complications, such as post-LP headache. In fact, a
number of studies over almost 20 years have shown that
LP is associated with mild headache in ,5% of subjects
[39–42], a frequency only slightly greater than is
observed after amyloid PET (1%–1.8%) [36,37,43].
Furthermore, recent clinical trials of anti-amyloid immuno-
therapies have increasingly moved toward using LP to
obtain CSF samples for analysis of biomarkers [44–46].
In some countries, the procedure is not yet routine and
physicians may require training and experience to
perform CSF collection.
The potential availability of DMTs in coming years
creates the need for reliable diagnostic tests to accurately
identify patients with amyloid pathology who are likely to
benefit most from these agents. Improved diagnostic tests
will also enrich clinical trial populations with the appro-
priate, amyloid-positive patients, thereby increasing the
likelihood that further DMTs will emerge. Along with am-
yloid PET imaging, CSF Ab (1–42) testing is now re-
garded as an essential pillar of AD diagnosis to identify
amyloid pathology as the underlying cause of symptoms
[4,47]. Furthermore, the combination of CSF tau
proteins (total and phosphorylated tau) with Ab (1–42)
is a sensitive and specific predictor of progression from
MCI to AD [5,6] and has the potential to assist with
differential diagnosis of AD from other causes of
dementia, such as Creutzfeldt-Jakob disease [48,49],
frontotemporal dementia, and Lewy body dementia [50].
Given the weight of evidence supporting the utility of
CSF Ab (1–42) in AD diagnosis, the only significant bar-
rier remaining to routine clinical use is the variability in
measured Ab (1–42) levels [51], which results mainly
from limitations of available assays. Further evaluation
of individual assays in prospective, longitudinal clinical
trials will strengthen confidence in their use, but such tri-
als are not necessary at this point to establish the clinical
utility of the biomarkers themselves.
The results described here provide evidence that the
novel Elecsys b-amyloid (1–42) assay embodies many of
the desired attributes for an ideal assay, including marked
improvements in precision compared with available
T. Bittner et al. / Alzheimer’s & Dementia 12 (2016) 517-526 525assays, even between laboratories. Part of the improved
performance is certainly because of the fully automated
procedure on the cobas platform. In addition, the assay
is the first CSF Ab (1–42) assay standardized to an
JCTLM approved RMP, and all assay lots are standardized
to a sample set with target values derived from the RMP,
providing good lot-to-lot comparability. In conclusion, re-
sults from the Elecsys b-amyloid (1–42) assay will be
highly replicated across laboratories and lots. This repre-
sents a fundamental prerequisite for the establishment of
a robust cutoff value that is valid worldwide now and
into the future.
Acknowledgments
This study was funded by Roche Diagnostics GmbH and
supported by the Torsten S€oderberg Foundation at the Royal
Swedish Academy of Sciences, Stockholm, Sweden. Edito-
rial support in the form of medical writing services was pro-
vided by Ben Caldwell of MediTech Media Ltd and funded
by Roche Diagnostics GmbH.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jalz.2015.09.009.RESEARCH IN CONTEXT
1. Systematic review: We reviewed the literature using
PubMed and incorporated searches of conference ab-
stracts and assay datasheets. Available data on the
technical performance of alternative assays for quan-
titation of amyloid-beta 1–42 (Ab [1–42]) in human
cerebrospinal fluid (CSF) have been appropriately
reviewed and cited.
2. Interpretation: In our study, we have demonstrated
that a novel, fully automated assay for quantitation
of Ab (1–42) in human CSF has excellent reproduc-
ibility, including high lot-to-lot comparability. These
measures contrast with those of commercially
available assays for Ab (1–42), suggesting that this
assay might improve the precision of Ab (1–42)
quantitation in CSF. Furthermore, the assay is the
first to be standardized to a candidate reference
measurement procedure.
3. Future directions: Further research is required in the
clinical setting to evaluate a cutoff value with this
assay for Ab (1–42) that will guide its potential use
in the diagnostic setting in AD.References
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